ADARx Pharmaceuticals Inc. is a San Diego-based biotechnology company with a vision to provide effective and safe therapeutics for patients suffering from intractable diseases. The company specializes in developing proprietary RNA targeting platforms and oligonucleotide delivery technologies for inhibiting, degrading, and editing disease-causing mRNA. With a focus on genetic, cardiometabolic, complement-mediated, and central nervous system diseases, ADARx has a growing pipeline of RNA targeting therapeutics. Established in 2019, the company has secured significant funding from a syndicate of renowned VC firms, including HBM Healthcare Investments, BlackRock, Vivo Capital, Marshall Wace, Redmile Group, T. Rowe Price, Cormorant Asset Management, SR One, Venrock Healthcare Capital Partners, and Bain Capital Life Sciences. Their most recent Series C investment of $200.00M was received on 09 August 2023. ADARx's multiple active programs in development, including a lead candidate in the clinical stage, position the company as an innovative player in the biotechnology and pharmaceutical industries, with the potential to make a significant impact on the healthcare sector.
No recent news or press coverage available for ADARx Pharmaceuticals Inc..